Analysts Set Expectations for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at B. Riley issued their FY2024 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 7th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will earn ($0.83) per share for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. B. Riley also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.65) EPS.

NKTR has been the topic of several other research reports. BTIG Research reiterated a “buy” rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. Piper Sandler assumed coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, HC Wainwright initiated coverage on Nektar Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $6.50 target price on the stock. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.08.

Nektar Therapeutics Price Performance

Shares of NKTR opened at $1.14 on Friday. The business’s 50-day moving average is $1.09 and its 200-day moving average is $1.21. The company has a market capitalization of $210.28 million, a price-to-earnings ratio of -1.36 and a beta of 0.59. Nektar Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.93.

Insider Buying and Selling

In related news, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the sale, the insider now directly owns 351,892 shares of the company’s stock, valued at approximately $316,702.80. This represents a 8.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the transaction, the insider now owns 326,904 shares in the company, valued at $307,289.76. This trade represents a 13.52 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 155,575 shares of company stock worth $149,878. Corporate insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in shares of Nektar Therapeutics by 2,822.5% during the second quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 532,663 shares during the last quarter. Nantahala Capital Management LLC increased its position in Nektar Therapeutics by 66.0% during the second quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares during the period. Samlyn Capital LLC acquired a new position in Nektar Therapeutics during the 2nd quarter valued at $11,728,000. Millennium Management LLC boosted its holdings in Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after purchasing an additional 1,674,924 shares during the period. Finally, Eventide Asset Management LLC grew its position in Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after purchasing an additional 1,870,904 shares during the last quarter. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.